Low-Sodium Oxybate in the Treatment of Narcolepsy and Idiopathic Hypersomnia
An expert discusses the significance of low-sodium oxybate for patients with narcolepsy patients with and cardiovascular disease and compares the diagnostic criteria and clinical presentations of narcolepsy and idiopathic hypersomnia.
Video content above is prompted by the following:
- What is the significance of low-sodium oxybate formulations for patients with narcolepsy who have comorbid cardiovascular disease (CVD)?
- Low-sodium oxybate is also currently the only FDA-approved treatment for idiopathic hypersomnia (IH). How do the diagnostic criteria and clinical presentations of narcolepsy differ from those of IH?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Optimizing narcolepsy care: Diagnosis, treatment and patient access | Written recap
April 4th 2025In a recent Managed Healthcare Executive K-Cast video series, R. Robert Auger, M.D., a psychiatrist and sleep specialist at the Mayo Clinic in Rochester, Minnesota, spoke about the diagnosis and treatment of narcolepsy and idiopathic hypersomnia. This is a written recap of that series.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
